In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin

Lance B. Price; Amy Vogler; Talima Pearson; Joseph D. Busch; James M. Schupp; Paul Keim

doi:10.1128/AAC.47.7.2362-2365.2003

In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin

Lance B. Price, Amy Vogler, Talima Pearson, Joseph D. Busch, James M. Schupp, Paul Keim

Biological Sciences

Research output: Contribution to journal › Article › peer-review

101 Scopus citations

Abstract

Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

Original language	English (US)
Pages (from-to)	2362-2365
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	47
Issue number	7
DOIs	https://doi.org/10.1128/AAC.47.7.2362-2365.2003
State	Published - Jul 1 2003

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.47.7.2362-2365.2003

Cite this

@article{881732642e484b7ea4ff78ba40c82c6a,

title = "In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin",

abstract = "Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.",

author = "Price, {Lance B.} and Amy Vogler and Talima Pearson and Busch, {Joseph D.} and Schupp, {James M.} and Paul Keim",

year = "2003",

month = jul,

day = "1",

doi = "10.1128/AAC.47.7.2362-2365.2003",

language = "English (US)",

volume = "47",

pages = "2362--2365",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin

AU - Price, Lance B.

AU - Vogler, Amy

AU - Pearson, Talima

AU - Busch, Joseph D.

AU - Schupp, James M.

AU - Keim, Paul

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

AB - Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

UR - http://www.scopus.com/inward/record.url?scp=0038650918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038650918&partnerID=8YFLogxK

U2 - 10.1128/AAC.47.7.2362-2365.2003

DO - 10.1128/AAC.47.7.2362-2365.2003

M3 - Article

C2 - 12821500

AN - SCOPUS:0038650918

SN - 0066-4804

VL - 47

SP - 2362

EP - 2365

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 7

ER -

In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this